Recombinant Cynomolgus AGER Protein
Beta LifeScience
SKU/CAT #: BLK-00607P-100UG
Cynomolgus AGER on Tris-Bis PAGE under reduced condition. The purity is greater than 95%.
Recombinant Cynomolgus AGER Protein
Beta LifeScience
SKU/CAT #: BLK-00607P-100UG
Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.
Product Overview
| Description | Recombinant Cynomolgus AGER Protein is expressed from HEK293 with His tag at the C-Terminus.It contains Gln24-Thr354. |
| Purity | > 95% as determined by Tris-Bis PAGE |
| Accession | A0A2K5TSM4 |
| Target Symbol | AGER |
| Species | Cynomolgus |
| Expression System | HEK293 |
| Tag | C-His |
| Expression Range | Gln24-Thr354 |
| Mol. Weight | The protein has a predicted MW of 36.78 kDa. Due to glycosylation, the protein migrates to 50-65 kDa based on Tris-Bis PAGE result. |
| Form | Lyophilized |
| Formulation | Lyophilized from 0.22um filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization. |
| Endotoxin | Less than 1EU per ug by the LAL method. |
| Storage | Reconstituted protein stable at -80°C for 12 months, 4°C for 1 week. Use a manual defrost freezer and avoid repeated freeze-thaw cycles. |
| Shipping | Shipped at ambient temperature. |
| Gene Background | The receptor for advanced glycation end products (AGER) is an oncogenic transmembranous receptor up-regulated in various human cancers. AGER promotes proliferation, migration, and inhibits apoptosis of squamous cervical cancer and might function as a tumor promoter in cervical cancer. Our study provides novel evidence for a potential role of AGER in bridging human papillomavirus (HPV)-induced inflammation and cervical cancer. |
